237 related articles for article (PubMed ID: 36930857)
21. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
22. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
Scheid C; de Wreede L; van Biezen A; Koenecke C; Göhring G; Volin L; Maertens J; Finke J; Passweg J; Beelen D; Cornelissen JJ; Itälä-Remes M; Chevallier P; Russell N; Petersen E; Milpied N; Richard Espiga C; Peniket A; Sierra J; Mufti G; Crawley C; Veelken JH; Ljungman P; Cahn JY; Alessandrino EP; de Witte T; Robin M; Kröger N
Bone Marrow Transplant; 2017 Nov; 52(11):1519-1525. PubMed ID: 28892084
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
24. Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes.
Creignou M; Bernard E; Gasparini A; Tranberg A; Todisco G; Moura PL; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Elena C; Ferrari J; Gallì A; Pozzi S; Malcovati L; Edgren G; Crowther MJ; Jädersten M; Papaemmanuil E; Hellström-Lindberg E
J Intern Med; 2024 Jul; 296(1):53-67. PubMed ID: 38654517
[TBL] [Abstract][Full Text] [Related]
25. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
Sabile JMG; Kaempf A; Tomic K; Manu GP; Swords R; Migdady Y
Leuk Lymphoma; 2023 Oct; 64(10):1689-1694. PubMed ID: 37440338
[TBL] [Abstract][Full Text] [Related]
26. Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
Hoff FW; Madanat YF
Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
[TBL] [Abstract][Full Text] [Related]
27. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D
Leuk Lymphoma; 2019 Jun; 60(6):1522-1527. PubMed ID: 30499738
[TBL] [Abstract][Full Text] [Related]
28. Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes.
Yu Y; Zhang T; Bao X; Wang Q; Zhang L; Hong Y; Zeng Z; Shen H; Wu D; Pan J; Liu H; Chen S; Sun A
Leuk Lymphoma; 2020 Apr; 61(4):919-926. PubMed ID: 31842651
[TBL] [Abstract][Full Text] [Related]
29. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
GenoMed4All consortium
Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
31. Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
Ball S; Komrokji RS; Sallman DA
Leuk Lymphoma; 2022 Jun; 63(6):1281-1291. PubMed ID: 34933652
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome.
Ma J; Gu Y; Wei Y; Wang X; Wang P; Song C; Ge Z
Blood Sci; 2023 Jul; 5(3):187-195. PubMed ID: 37546714
[TBL] [Abstract][Full Text] [Related]
34. Incorporating mutations and bone marrow fibrosis into the revised international prognostic scoring system in myelodysplastic syndromes.
Zhao Y; Guo J; Zhao S; Wang R; Wu D; Chang C
Leuk Lymphoma; 2024 Jan; 65(1):100-108. PubMed ID: 37865969
[TBL] [Abstract][Full Text] [Related]
35. Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.
Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Choi YS; Kim DY; Lee JH; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Lee JW; Lee KH; Min WS; Lee JH; Kim YJ
Bone Marrow Transplant; 2017 Apr; 52(4):522-531. PubMed ID: 27892952
[TBL] [Abstract][Full Text] [Related]
36. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
[TBL] [Abstract][Full Text] [Related]
37. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
DeZern AE; Greenberg PL
J Natl Compr Canc Netw; 2022 Dec; 20(12):1280-1283. PubMed ID: 36509078
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
Bektaş Ö; Üner A; Eliaçık E; Uz B; Işık A; Etgül S; Bozkurt S; Haznedaroğlu İC; Göker H; Sayınalp N; Aksu S; Demiroğlu H; Özcebe Oİ; Büyükaşık Y
Turk J Haematol; 2016 Jun; 33(2):119-26. PubMed ID: 26376664
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
40. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]